Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bora Pharmaceuticals CoBORAY 70 EV-to-EBITDA is 3.69 as of Jul. 21, 2026, which is 75% below its 10-year median of 14.86. GuruFocus rates BORAY with a GF Score™ of 70/100 and a GF Value™ of $4.84 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 741 Drug Manufacturers companies, Bora Pharmaceuticals Co ranks better than 65.18% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bora Pharmaceuticals Co's enterprise value is $798.1 Mil.
Bora Pharmaceuticals Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $216.1 Mil. Therefore, Bora Pharmaceuticals Co's EV-to-EBITDA for today is 3.69.
The historical rank and industry rank for Bora Pharmaceuticals Co's EV-to-EBITDA or its related term are showing as below:
BORAY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.62 Med: 14.86 Max: 66.96
Current: 9.58
During the past 13 years, the highest EV-to-EBITDA of Bora Pharmaceuticals Co was 66.96. The lowest was 5.62. And the median was 14.86.
BORAY's EV-to-EBITDA is ranked better than 65.18% of 741
companies
in the Drug Manufacturers industry
Industry Median: 13.1
vs BORAY: 9.58
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Bora Pharmaceuticals Co (OTCPK:BORAY) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bora Pharmaceuticals Co's PE Ratio (TTM) for today is calculated as:
Bora Pharmaceuticals Co's share price for today is $2.59.
Bora Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.732.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bora Pharmaceuticals Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bora Pharmaceuticals Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bora Pharmaceuticals Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bora Pharmaceuticals Co's EV-to-EBITDA falls into.
Bora Pharmaceuticals Co's current Enterprise Value is $798.1 Mil.
Bora Pharmaceuticals Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $216.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bora Pharmaceuticals Co (BORAY) has a EV-to-EBITDA of 3.69 as of Jul. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bora Pharmaceuticals Co. This is 75% below median its historical median of 14.86. Over the past decade, Bora Pharmaceuticals Co's EV-to-EBITDA has ranged from 5.62 to 66.96. According to the industry distribution chart, Bora Pharmaceuticals Co ranks #258 out of 741 companies in the Drug Manufacturers industry, placing it in the top 34.8%.
Is Bora Pharmaceuticals Co's EV-to-EBITDA too high?
Bora Pharmaceuticals Co's current EV-to-EBITDA of 3.69 is 75% below median its 10-year median of 14.86. Over the past 10 years, this metric has ranged from a low of 5.62 to a high of 66.96. The Drug Manufacturers industry median EV-to-EBITDA is 13.10. Bora Pharmaceuticals Co's value of 3.69 is 71.8% below this industry median. Based on the distribution chart, Bora Pharmaceuticals Co ranks #258 out of 741 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bora Pharmaceuticals Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's EV-to-EBITDA compare to ?
According to the Drug Manufacturers industry distribution chart, Bora Pharmaceuticals Co ranks #258 out of 741 companies for EV-to-EBITDA. This puts Bora Pharmaceuticals Co in the upper half of its industry. The industry median EV-to-EBITDA is 13.10. Bora Pharmaceuticals Co's value of 3.69 is 71.8% below this benchmark. Historically, Bora Pharmaceuticals Co's own EV-to-EBITDA has ranged from 5.62 to 66.96 over the past decade. While the company's 10-year median is 14.86 vs. the industry median of 13.10, Bora Pharmaceuticals Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.10, based on 741 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bora Pharmaceuticals Co's current EV-to-EBITDA of 3.69 is 71.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bora Pharmaceuticals Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bora Pharmaceuticals Co's current EV-to-EBITDA is 3.69, which is 75% below median its own 10-year median of 14.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (BORAY) is currently considered Significantly Undervalued. The stock's GF Value™ is $4.84, compared to a current price of $2.59 — trading 46.5% below its estimated fair value. The current EV-to-EBITDA is 3.69, which is 75% below median its 10-year median of 14.86 and 71.8% below the Drug Manufacturers industry median of 13.10. Bora Pharmaceuticals Co's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bora Pharmaceuticals Co (BORAY), the current EV-to-EBITDA is 3.69 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bora Pharmaceuticals Co (BORAY) Overvalued in 2026?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued.
The current stock price of $2.59 is trading 46.5% below its estimated GF Value™ of $4.84.
GuruFocus considers Bora Pharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for BORAY:
EV-to-EBITDA: 3.69 (75% below median its 10-year median of 14.86)
GF Value™: $4.84 vs. price of $2.59 (46.5% below fair value)
Industry Position: 71.8% below the Drug Manufacturers median (#258 of 741)
No single metric tells the full story. See the BORAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
70GF Score
Get the complete analysis for BORAY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BORAY has been successfully added to your 
